SCHEMBL726982

SCHEMBL726982

CCCCCCCC/C=C(/CCCCCCCC)OCC[O]

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 9/20 0.44
PPARA Q07869 5/20 0.44
TERT O14746 3/20 0.44
PTPN1 P18031 3/20 0.44
PPARD Q03181 3/20 0.44
MAPT P10636 2/20 0.44
BLM P54132 2/20 0.44
HSD17B10 Q99714 2/20 0.44
FABP4 P15090 2/20 0.44
GMNN O75496 1/20 0.44
USP2 O75604 1/20 0.44
LMNA P02545 1/20 0.44
CYP1A2 P05177 1/20 0.44
POLB P06746 1/20 0.44
CYP2C9 P11712 1/20 0.44
ALOX15 P16050 1/20 0.44
APEX1 P27695 1/20 0.44
CYP2C19 P33261 1/20 0.44
RECQL P46063 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5821498 0.84 DGKA (0.47) PPARGPPARAPTPN1PPARDMAPT
Ethylene Glycol SCHEMBL14958387 0.83 PPARG (0.42) PPARGPPARATERTPTPN1PPARD
SCHEMBL28218359 0.82 FAAH (0.50) PPARGPPARATERTPTPN1PPARD
SCHEMBL7970049 0.78 EPHX2 (0.49) PPARGPPARATERTPTPN1PPARD
SCHEMBL11130007 0.77 EP300 (0.45) PPARGPPARATERTPTPN1PPARD
SCHEMBL11005625 0.77 EP300 (0.45) PPARGPPARATERTPTPN1PPARD
SCHEMBL11805820 0.77 EP300 (0.45) PPARGPPARATERTPTPN1PPARD
SCHEMBL1502818 0.77 EP300 (0.45) PPARGPPARATERTPTPN1PPARD
SCHEMBL11130016 0.77 EP300 (0.45) PPARGPPARATERTPTPN1PPARD
SCHEMBL11005612 0.77 EP300 (0.45) PPARGPPARATERTPTPN1PPARD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3073263-B1 DEVICE, COMPOSITION AND METHOD FOR TISSUE-BASED DIAGNOSIS UNIV CALIFORNIA (US) 2020-04-29 EP claimed
US-9848853-B2 System, method and devices for tissue-based diagnosis THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2017-12-26 US claimed
EP-3073263-A1 SYSTEM, METHOD AND DEVICE FOR TISSUE-BASED DIAGNOSIS The Regents of the University of California (US) 2016-09-28 EP claimed
US-20160235392-A1 SYSTEM, METHOD AND DEVICES FOR TISSUE-BASED DIAGNOSIS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2016-08-18 US claimed
US-9328324-B2 System, method and devices for tissue-based diagnosis THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2016-05-03 US claimed
US-20150344834-A1 System, Method and Devices for Tissue-Based Diagnosis THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2015-12-03 US claimed
CN-104655828-A SYSTEM, METHOD AND DEVICE FOR TISSUE-BASED DIAGNOSIS UNIV CALIFORNIA 2015-05-27 CN claimed
US-8945482-B2 System, method and device for tissue-based diagnosis THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2015-02-03 US claimed
EP-2575807-B1 FORMULATION BASED ON SULPIRIDE AND A SYNERGISTIC HOMEOPATHIC COMPOSITION FOR TREATMENT OF DEPRESSIVE SYNDROME NOVAK MAJA (HR) 2014-02-19 EP claimed
EP-1436435-B1 METHOD OF ANODIZING OF MAGNESIUM AND MAGNESIUM ALLOYS AND PRODUCING CONDUCTIVE LAYERS ON AN ANODIZED SURFACE ALONIM HOLDING AGRICULTURAL CO (IL) 2010-04-14 EP claimed
US-20070161030-A1 Micelle-and microemulsion-assisted planar separations platform for proteomics PERKINELMER LAS, INC. 2007-07-12 US claimed
WO-2007067731-A2 MICELLE- AND MICROEMULSION-ASSISTED PLANAR SEPARATIONS PLATFORM FOR PROTEOMICS PERKINELMER LAS, INC. (US) 2007-06-14 WO claimed
US-9848853-B2 System, method and devices for tissue-based diagnosis THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2017-12-26 US disclosed
EP-1774276-B1 METHODS AND COMPOSITIONS FOR DETECTING AND ISOLATING PHOSPHORYLATED MOLECULES USING HYDRATED METAL OXIDES PERKINELMER HEALTH SCI INC (US) 2017-06-07 EP disclosed
US-20170050044-A1 Integumentary System Therapy LEBOVITZ RUSSELL M (US) 2017-02-23 US disclosed
US-9562895-B2 Assay particles and methods of use PERKINELMER HEALTH SCIENCES, INC. (US) 2017-02-07 US disclosed
EP-1476121-A1 TOPICAL IVERMECTIN COMPOSITION Merck & Co., Inc. (US) 2004-11-17 EP disclosed
WO-2003066009-A1 TOPICAL IVERMECTIN COMPOSITION MERCK & CO., INC. (US) 2003-08-14 WO disclosed
US-5877209-A THE ANTIOXIDANT OR FREE RADICAL BLOCKING AGENT IS ASCORBIC-ACID, BUTYLATED HYDROXYTOLUENE (BHT), BUTYLATED HYDROXYANISOLE (BHA), A MIXTURE OF ASCORBIC ACID AND BHT OR BHA OR A BLEND OF TOCOPHEROLS AND ASCORBIC ACID. YUNIS ADEL A (US) 1999-03-02 US disclosed
US-4673569-A FILM FORMING POLYVINYLPYRROLIDONE WITH DIESTER OF DIETHYLENE GLYCOL AND SODIUM BENZOATE FABERGE INCORPORATED (US) 1987-06-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170050044-A1 Integumentary System Therapy OTC, SUCLG1, TYR PPARG 4407/4885PPARA 4317/4885TERT 2055/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.